自动化胰岛素输送系统的研究差距、挑战和机遇。

IF 6.3 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Peter G Jacobs, Carol J Levy, Sue A Brown, Michael C Riddell, Ali Cinar, Charlotte K Boughton, Marc D Breton, Eyal Dassau, Greg Forlenza, Robert J Henderson, Roman Hovorka, David M Maahs, Medha Munshi, Helen Murphy, Sarit Polsky, Richard Pratley, Melissa S Putman, Viral N Shah, Leah M Wilson, Howard Zisser, Laya Ekhlaspour
{"title":"自动化胰岛素输送系统的研究差距、挑战和机遇。","authors":"Peter G Jacobs, Carol J Levy, Sue A Brown, Michael C Riddell, Ali Cinar, Charlotte K Boughton, Marc D Breton, Eyal Dassau, Greg Forlenza, Robert J Henderson, Roman Hovorka, David M Maahs, Medha Munshi, Helen Murphy, Sarit Polsky, Richard Pratley, Melissa S Putman, Viral N Shah, Leah M Wilson, Howard Zisser, Laya Ekhlaspour","doi":"10.1089/dia.2025.0129","DOIUrl":null,"url":null,"abstract":"<p><p>Since the discovery of the life-saving hormone insulin in 1921 by Dr. Frederick Banting in 1921, there have been many critical discoveries and technical breakthroughs that have enabled people living with type 1 diabetes (T1D) to live longer, healthier lives. The development of insulin pumps, continuous glucose monitoring systems, and automated insulin delivery (AID) systems has enabled people living with T1D to safely manage their glucose, reduce their HbA1c, and improve their overall health and quality of life. Nevertheless, AID systems are not yet designed for all people with T1D, and they perform best during the overnight period when meals and exercise are not occurring. AID systems are not fully automated in that they require the person using the system to announce meals and exercise to the system to avoid dangerous hyper- or hypoglycemia, respectively. In this review, which is one of a collection of articles to commemorate the 75th anniversary of the National Institute for Diabetes and Digestive and Kidney Diseases, we celebrate the commercialization of the AID and discuss the major challenges and research gaps that remain to be solved to enable single- and multihormone AID systems to more fully support glucose management in people living with T1D. More research is required to design and evaluate more intelligent AID systems that do not require accurate carbohydrate estimations or announcements for meals and exercise. Current AID systems are also not designed to be used by older adults or pregnant people. Results are presented on new AID systems that can automatically respond to meals and exercise. Results are also presented on evaluations of AID systems in older adults and pregnant people. Next-generation AID systems will need to support all people, including older adults, people during pregnancy, athletes, and people who may be too busy to announce carbohydrates or exercise to the system. Solutions are now becoming available that will enable AID systems to support a broader range of people living with T1D by leveraging the latest technologies in artificial intelligence and adaptive control.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":"27 S3","pages":"S60-S71"},"PeriodicalIF":6.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems.\",\"authors\":\"Peter G Jacobs, Carol J Levy, Sue A Brown, Michael C Riddell, Ali Cinar, Charlotte K Boughton, Marc D Breton, Eyal Dassau, Greg Forlenza, Robert J Henderson, Roman Hovorka, David M Maahs, Medha Munshi, Helen Murphy, Sarit Polsky, Richard Pratley, Melissa S Putman, Viral N Shah, Leah M Wilson, Howard Zisser, Laya Ekhlaspour\",\"doi\":\"10.1089/dia.2025.0129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Since the discovery of the life-saving hormone insulin in 1921 by Dr. Frederick Banting in 1921, there have been many critical discoveries and technical breakthroughs that have enabled people living with type 1 diabetes (T1D) to live longer, healthier lives. The development of insulin pumps, continuous glucose monitoring systems, and automated insulin delivery (AID) systems has enabled people living with T1D to safely manage their glucose, reduce their HbA1c, and improve their overall health and quality of life. Nevertheless, AID systems are not yet designed for all people with T1D, and they perform best during the overnight period when meals and exercise are not occurring. AID systems are not fully automated in that they require the person using the system to announce meals and exercise to the system to avoid dangerous hyper- or hypoglycemia, respectively. In this review, which is one of a collection of articles to commemorate the 75th anniversary of the National Institute for Diabetes and Digestive and Kidney Diseases, we celebrate the commercialization of the AID and discuss the major challenges and research gaps that remain to be solved to enable single- and multihormone AID systems to more fully support glucose management in people living with T1D. More research is required to design and evaluate more intelligent AID systems that do not require accurate carbohydrate estimations or announcements for meals and exercise. Current AID systems are also not designed to be used by older adults or pregnant people. Results are presented on new AID systems that can automatically respond to meals and exercise. Results are also presented on evaluations of AID systems in older adults and pregnant people. Next-generation AID systems will need to support all people, including older adults, people during pregnancy, athletes, and people who may be too busy to announce carbohydrates or exercise to the system. Solutions are now becoming available that will enable AID systems to support a broader range of people living with T1D by leveraging the latest technologies in artificial intelligence and adaptive control.</p>\",\"PeriodicalId\":11159,\"journal\":{\"name\":\"Diabetes technology & therapeutics\",\"volume\":\"27 S3\",\"pages\":\"S60-S71\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes technology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/dia.2025.0129\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2025.0129","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

自1921年Frederick Banting博士发现救命激素胰岛素以来,有许多重要的发现和技术突破使1型糖尿病患者(T1D)活得更长,更健康。胰岛素泵、连续血糖监测系统和自动胰岛素输送(AID)系统的发展使T1D患者能够安全地控制血糖,降低HbA1c,改善他们的整体健康和生活质量。然而,AID系统并不是为所有T1D患者设计的,它们在没有吃饭和锻炼的夜间表现最好。AID系统并不是完全自动化的,因为它们需要使用该系统的人分别向系统宣布吃饭和锻炼,以避免危险的高血糖或低血糖。这篇综述是纪念美国国家糖尿病、消化和肾脏疾病研究所成立75周年的系列文章之一,我们庆祝了AID的商业化,并讨论了仍有待解决的主要挑战和研究差距,以使单激素和多激素AID系统能够更充分地支持T1D患者的葡萄糖管理。需要更多的研究来设计和评估更智能的AID系统,这些系统不需要精确的碳水化合物估计或膳食和运动通知。目前的艾滋病系统也不是为老年人或孕妇设计的。结果显示在新的AID系统上,该系统可以自动对饮食和锻炼做出反应。还介绍了对老年人和孕妇的艾滋病系统的评估结果。下一代AID系统需要支持所有人,包括老年人、孕妇、运动员以及可能太忙而无法向系统通报碳水化合物或运动的人。通过利用人工智能和自适应控制方面的最新技术,现在可以使用的解决方案将使AID系统能够支持更广泛的T1D患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems.

Since the discovery of the life-saving hormone insulin in 1921 by Dr. Frederick Banting in 1921, there have been many critical discoveries and technical breakthroughs that have enabled people living with type 1 diabetes (T1D) to live longer, healthier lives. The development of insulin pumps, continuous glucose monitoring systems, and automated insulin delivery (AID) systems has enabled people living with T1D to safely manage their glucose, reduce their HbA1c, and improve their overall health and quality of life. Nevertheless, AID systems are not yet designed for all people with T1D, and they perform best during the overnight period when meals and exercise are not occurring. AID systems are not fully automated in that they require the person using the system to announce meals and exercise to the system to avoid dangerous hyper- or hypoglycemia, respectively. In this review, which is one of a collection of articles to commemorate the 75th anniversary of the National Institute for Diabetes and Digestive and Kidney Diseases, we celebrate the commercialization of the AID and discuss the major challenges and research gaps that remain to be solved to enable single- and multihormone AID systems to more fully support glucose management in people living with T1D. More research is required to design and evaluate more intelligent AID systems that do not require accurate carbohydrate estimations or announcements for meals and exercise. Current AID systems are also not designed to be used by older adults or pregnant people. Results are presented on new AID systems that can automatically respond to meals and exercise. Results are also presented on evaluations of AID systems in older adults and pregnant people. Next-generation AID systems will need to support all people, including older adults, people during pregnancy, athletes, and people who may be too busy to announce carbohydrates or exercise to the system. Solutions are now becoming available that will enable AID systems to support a broader range of people living with T1D by leveraging the latest technologies in artificial intelligence and adaptive control.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信